News

DANBIO: Anti-TNFs Do Not Up Overall Cancer Risk


 

FROM THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY

DANBIO is financially supported by grants from the Danish Rheumatism Association and the Danish Cancer Society. Dr. Hetland has acted as a consultant to Roche, and has received grants and research support on behalf of DANBIO from Abbott, BMS, Centocor, Roche, Schering-Plough, UCB-Nordic, and Wyeth. Dr. Dreyer had no disclosures. Dr. Schett was not involved in the study.

Pages

Recommended Reading

Juvenile Dermatomyositis Is Easily Missed Diagnosis
Psoriasis Collection
Platelet C4d Predicts Cardiovascular Events, Mortality in Lupus
Psoriasis Collection
Treating Psoriasis During Pregnancy Presents Unique Challenges
Psoriasis Collection
Ustekinumab 4-Year Data Show No Increased Cardiovascular Risk
Psoriasis Collection
Off-Label Uses for Biologics Growing
Psoriasis Collection
Rare Lymphoma Reports Continue in Young Patients on TNF Blockers
Psoriasis Collection
Anti-TNFs in Pregnancy Study Advises Continued Caution
Psoriasis Collection
Interrupting Biologics Possible, Not Ideal
Psoriasis Collection
TRACTISS to Study Rituximab Effects in Sjögren's Syndrome
Psoriasis Collection
Interaction Between Adalimumab With Concurrent Pregabalin and Duloxetine Administration in a Psoriasis Patient With Diabetic Peripheral Neuropathy [letter]
Psoriasis Collection